PT  - JOURNAL ARTICLE
AU  - Hernandez, Matthew M.
AU  - Gonzalez-Reiche, Ana S.
AU  - Alshammary, Hala
AU  - Fabre, Shelcie
AU  - Khan, Zenab
AU  - van De Guchte, Adriana
AU  - Obla, Ajay
AU  - Ellis, Ethan
AU  - Sullivan, Mitchell J.
AU  - Tan, Jessica
AU  - Alburquerque, Bremy
AU  - Soto, Juan
AU  - Wang, Ching-Yi
AU  - Sridhar, Shwetha Hara
AU  - Wang, Ying-Chih
AU  - Smith, Melissa
AU  - Sebra, Robert
AU  - Paniz-Mondolfi, Alberto E.
AU  - Gitman, Melissa R.
AU  - Nowak, Michael D.
AU  - Cordon-Cardo, Carlos
AU  - Luksza, Marta
AU  - Krammer, Florian
AU  - van Bakel, Harm
AU  - Simon, Viviana
AU  - Sordillo, Emilia Mia
TI  - Before the Surge: Molecular Evidence of SARS-CoV-2 in New York City Prior to the First Report
AID  - 10.1101/2021.02.08.21251303
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.08.21251303
4099  - http://medrxiv.org/content/early/2021/02/11/2021.02.08.21251303.short
4100  - http://medrxiv.org/content/early/2021/02/11/2021.02.08.21251303.full
AB  - New York City (NYC) emerged as a coronavirus disease 2019 (COVID-19) epicenter in March 2020, but there is limited information regarding potentially unrecognized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections before the first reported case. We utilized a sample pooling strategy to screen for SARS-CoV-2 RNA in de-identified, respiratory pathogen-negative nasopharyngeal specimens from 3,040 patients across our NYC health system who were evaluated for respiratory symptoms or influenza-like illness during the first 10 weeks of 2020. We obtained complete SARS-CoV-2 genome sequences from samples collected between late February and early March. Additionally, we detected SARS-CoV-2 RNA in pooled specimens collected in the week ending 25 January 2020, indicating that SARS-CoV-2 caused sporadic infections in NYC a full month before the first officially documented case.ONE SENTENCE SUMMARY Molecular surveillance demonstrates that SARS-CoV-2 caused influenza-like illness in NYC before the first reported case.Competing Interest StatementRobert Sebra is VP of Technology Development and a stockholder at Sema4, a Mount Sinai Venture. This work, however, was conducted solely at Icahn School of Medicine at Mount Sinai.Funding StatementThe Research reported in this paper was supported by the National Institutes of Health (NIH) contract number HHSN272201400008C, the NIH Office of Research Infrastructure under award numbers S10OD018522 and S10OD026880, as well as institutional and philanthropic funds (Open Philanthropy Project, #2020-215611).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai (protocol: HS# 20-00141).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 genome consensus sequences for all study isolates and sample pools were deposited in GISAID.